The US CMS published their decision on test code and reimbursement price for Epi proColon on 22nd September. The decision means that the product is cross walked to test code 81287. The newly determined payments rates according to PAMA see the price increasing to $124 from $83, a 50% upside. This is an important milestone in the CMS reimbursement process which still needs to progress through national coverage determination following inclusion into medical guidelines. Given the need to see greater transparency on CMS coverage and hence forecasts we maintain our Neutral recommendation.
26 Sep 2017
A satisfying US reimbursement price
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
A satisfying US reimbursement price
Epigenomics AG (0QXH:LON) | 0 0 0.0% | Mkt Cap: 24.5m
- Published:
26 Sep 2017 -
Author:
Tim Franklin -
Pages:
5
The US CMS published their decision on test code and reimbursement price for Epi proColon on 22nd September. The decision means that the product is cross walked to test code 81287. The newly determined payments rates according to PAMA see the price increasing to $124 from $83, a 50% upside. This is an important milestone in the CMS reimbursement process which still needs to progress through national coverage determination following inclusion into medical guidelines. Given the need to see greater transparency on CMS coverage and hence forecasts we maintain our Neutral recommendation.